PLoS medicine

Links between substance use, psychosis, and death in people living in unstable housing or homelessness

Updated

Abstract

Among 437 adults, 79.3% reported psychotic features at least once during the first year of observation.

  • Methamphetamine use was associated with an increased risk of psychotic features, with a higher frequency of use correlating to greater risk.
  • Alcohol and cannabis use were also linked to higher odds of experiencing psychotic features.
  • Experiencing traumatic events concurrently was associated with increased likelihood of developing psychotic symptoms.
  • Baseline alcohol dependence and evidence of hepatic fibrosis were identified as risk factors for mortality.
  • Among participants under 55 years of age, a history of psychotic disorder was associated with a higher risk of mortality.

Simplified

Key numbers

79.3%
Psychotic Features Prevalence
Percentage of participants reporting psychotic features.
18.1%
Mortality Rate
Percentage of participants who died during the follow-up period.
1.83
Alcohol Dependence Hazard Ratio
Adjusted hazard ratio for mortality related to alcohol dependence.

Full Text

What this is

  • This study investigates the relationships between substance use, , and mortality among adults living in precarious housing or homelessness in Vancouver, Canada.
  • It analyzes how various risk factors contribute to psychotic features and mortality risk over a median follow-up of 6.3 years.
  • The sample included 437 adults, with a significant prevalence of substance use and psychotic features observed.

Essence

  • Substance use, particularly methamphetamine, alcohol, and cannabis, is associated with increased psychotic features among individuals living in precarious housing. Additionally, alcohol dependence and hepatic fibrosis are linked to higher mortality risk.

Key takeaways

  • Methamphetamine, alcohol, and cannabis use are linked to higher odds of psychotic features, with dose-dependent effects observed. A history of psychotic disorder and recent trauma also increase these odds.
  • Among participants under 55 years, a past history of psychotic disorder significantly increases mortality risk, alongside alcohol dependence and hepatic fibrosis.
  • The study underscores the importance of addressing modifiable risk factors, such as substance use, in interventions targeting individuals experiencing precarious housing or homelessness.

Caveats

  • Generalizability is limited due to the community-based sample, which may not reflect specific diagnostic groups in clinical settings. Additionally, missing family history data may affect the analysis.
  • The study's observational nature means causation cannot be established, and the effects of substance use may vary based on individual circumstances.

Definitions

  • psychosis: A mental state characterized by impaired reality testing, often manifesting as hallucinations and delusions.
  • trimorbidity: The co-occurrence of substance use disorder, mental illness, and physical health issues, commonly seen in marginalized populations.

Simplified

Funding

Competing interests

I have read the journal’s policy and the authors of this manuscript have the following competing interests: WGH has received consulting fees or sat on paid advisory boards for In Silico, Otsuka/Lundbeck, Newron, AlphaSights, the Centre for Drug Research and Development, and the Canadian Agency for Drugs and Technology in Health. He was additionally supported by the Jack Bell Chair in Schizophrenia. FVR received research support from Canadian Institutes of Health Research (CIHR), Brain Canada, Michael Smith Foundation for Health Research, and Vancouver Coastal Health Research Institute; received in-kind equipment support for this investigator-initiated trial from MagVenture; and has been on an advisory board for Janssen. RMP has been a member of the following advisory boards in the past 3 years: Janssen, Lundbeck, and Otsuka; a member of the following speaker’s bureaus in the past 3 years: Janssen, Lundbeck, and Otsuka; and received grants from the Canadian Institutes of Health Research. GWM has received consulting fees or sat on paid advisory boards for: Apotex, AstraZeneca, BMS, Janssen, Lundbeck, Otsuka, Pfizer, and Sunovion. He also received fees for lectures sponsored by AstraZeneca, BMS, Janssen, Otsuka, and Eli Lilly, and has received grants from Janssen Pharmaceuticals. JSGM has received institutional grants from Gilead Sciences, J&J, Merck, ViiV Healthcare, and a Knowledge Translation Award from the Canadian Institutes of Health Research. JSGM has also served as an advisor to Government of Canada and the Government of British Columbia in the last year. AET has received grants from the Canadian Institutes of Health Research (CIHR) and the William and Ada Isabelle Steel Fund. This does not alter our adherence to PLOS Medicine policies on sharing data and materials. AAJ, KMG, SS, TSW, OL, GNS, TAS, ATV, TB, AR, DJL, VDL, WJP, and AMB declared that no competing interests exist.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free